OncoMatch/Clinical Trials/NCT06075810
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
Is NCT06075810 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies MBQ-167 for breast cancer.
Treatment: MBQ-167 — A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
MBQ-167
Cancer type
Breast Carcinoma
Demographics
Ages ≥ 21
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Precision Next Gen Oncology & Research Center · Beverly Hills, California
- Florida Cancer Specialists / Sarah Cannon Research Institute / SCRI · Sarasota, Florida
- Sarah Cannon Research Institute/SCRI · Nashville, Tennessee
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06075810 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages